The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components

Neurochemical Research

Volumn 29, Issue 6, 2004, Pages 1179-1188

  Connolly, Patrick M ^a,b   Maxwell, Christina ^a,b   Liang, Yuling ^a,b   Kahn, Jonathan B ^a,b   Kanes, Stephen J ^b   Abel, Ted ^a   Gur, Raquel E ^b   Turetsky, Bruce I ^b   Siegel, Steven J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Auditory evoked potential; ERP; Ketamine; Mouse; N100; NMDA; P50, P200; Schizophrenia

Indexed keywords

KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROTEIN P50; N METHYLASPARTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; EVENT RELATED POTENTIAL; EVOKED AUDITORY RESPONSE; GENETIC VARIABILITY; HYPOTHESIS; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; ANIMAL; ARTICLE; C3H MOUSE; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DBA MOUSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; SPECIES DIFFERENCE;

ANIMALIA;

ANIMALS; DISEASE MODELS, ANIMAL; EVOKED POTENTIALS, AUDITORY; HUMANS; KETAMINE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, INBRED STRAINS; N-METHYLASPARTATE; SCHIZOPHRENIA; SPECIES SPECIFICITY;

EID: 3142762940     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NERE.0000023605.68408.fb     Document Type: Review

References (68)

1. Boutros, N. N., Belger, A., Campbell, D., D'Souza, C., and Krystal, J. 1999. Comparison of four components of sensory gating in schizophrenia and normal subjects: a preliminary report. Psychiatry Res. 88(2):119-30.
2. Catts, S. V., Shelley, A. M., Ward, P. B., Liebert, B., McConaghy, N., Andrews, S., and Michie, P. T. 1995. Brain potential evidence for an auditory sensory memory deficit in schizophrenia. Am. J. Psychiatry 152(2):213-9.
3. Freedman, R., Adler, L. E., Waldo, M. C., Pachtman, E., and Franks, R. D. 1983. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol. Psychiatry 18(5):537-51.
4. Javitt, D. C., Doneshka, P., Zylberman, I., Ritter, W., and Vaughan, H. G., Jr. 1993. Impairment of early cortical processing in schizophrenia: an event-related potential confirmation study. Biol. Psychiatry 33(7):513-9.
5. Mathalon, D. H., Ford, J. M., and Pfefferbaum, A. 2000. Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study. Biol. Psychiatry 47(5):434-49.
6. Shelley, A. M., Ward, P. B., Catts, S. V., Michie, P. T., Andrews, S., and McConaghy, N. 1991. Mismatch negativity: an index of a preattentive processing deficit in schizophrenia. Biol. Psychiatry 30(10):1059-62.
7. Adler, L. E., Hoffer, L. J., Griffith, J., Waldo, M. C., and Freedman, R. 1992. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol. Psychiatry 32(7):607-16.
8. Freedman, R., Adler, L. E., Bickford, P., Byerley, W., Coon, H., Cullum, C. M., Griffith, J. M., Harris, J. G., Leonard, S., Miller, C., and et al. 1994. Schizophrenia and nicotinic receptors. Harvard Review of Psychiatry 2(4):179-92.
9. Siegel, C., Waldo, M., Mizner, G., Adler, L. E., and Freedman, R. 1984. Deficits in sensory gating in schizophrenic patients and their relatives. Evidence obtained with auditory evoked responses. Arch. Gen. Psychiatry 41(6):607-12.
10. Javitt, D. C., Steinschneider, M., Schroeder, C. E., and Arezzo, J. C. 1996. Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc. Natl. Acad. Sci. USA 93(21): 11962-7.
11. Leonard, S., Adams, C., Breese, C. R., Adler, L. E., Bickford, P., Byerley, W., Coon, H., Griffith, J. M., Miller, C., Myles-Worsley, M., Nagamoto, H. T., Rollins, Y., Stevens, K. E., Waldo, M., and Freedman, R. 1996. Nicotinic receptor function in schizophrenia. Schizophr. Bull. 22(3):431-45.
12. Pincze, Z., Lakatos, P., Rajkai, C., Ulbert, I., and Karmos, G. 2001. Separation of mismatch negativity and the N1l wave in the auditory cortex of the cat: a topographic study. Clin. Neurophysiol. 112(5):778-84.
13. Ruusuvirta, T. 1999. From spatial acoustic changes to attentive behavioral responses within 200 ms in humans. Neurosci. Lett. 275(1):49-52.
14. Bullock, A. E., Slobe, B. S., Vazquez, V., and Collins, A. C. 1997. Inbred mouse strains differ in the regulation of startle and pre-pulse inhibition of the startle response. Behav. Neurosci. 111(6): 1353-60.
15. d'Amato, T., Karoumi, B., Rosenfeld, F., Saoud, M., Brunon, A. M., and Dalery, J. 1999. [Vulnerability to schizophrenia. II: Familial status of auditory evoked potential abnormalities]. Encephale 25(4):288-95.
16. Stevens, K. E., Freedman, R., Collins, A. C., Hall, M., Leonard, S., Marks, M. J., and Rose, G. M. 1996. Genetic correlation of inhibitory gating of hippocampal auditory evoked response and α-bungerotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 15(2):152-162.
17. Duncan, G. E., Miyamoto, S., Leipzig, J. N., and Lieberman, J. A. 1999. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res. 843(1-2):171-83.
18. Etienne, P. and Baudry, M. 1990. Role of excitatory amino acid neurotransmission in synaptic plasticity and pathology. An integrative hypothesis concerning the pathogenesis and evolutionary advantages of schizophrenia-related genes. J Neural. Transm. Suppl. 29:39-48.
19. Kerwin, R., Patel, S., and Meldrum, B. 1990. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 39(1):25-32.
20. McCarley, R. W., Faux, S. F., Shenton, M. E., Nestor, P. G., and Adams, J. 1991. Event-related potentials in schizophrenia: their biological and clinical correlates and a new model of schizophrenic pathophysiology. Schizophr. Res. 4(2):209-31.
21. Javitt, D. C. and Zukin, S. R. 1991. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148(10): 1301-8.
22. Lahti, A. C., Weiler, M. A., Tamara Michaelidis, B. A., Parwani, A., and Tamminga, C. A. 2001. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25(4): 455-67.
23. Newcomer, J. W., Farber, N. B., Jevtovic-Todorovic, V., Selke, G., Melson, A. K., Hershey, T., Craft, S., and Olney, J. W. 1999. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20(2):106-18.
24. Vollenweider, F. X., Vontobel, P., Oye, I., Hell, D., and Leenders, K. L. 2000. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J. Psychiatr. Res. 34(1):35-43.
25. Abi-Dargham, A., Laruelle, M., Lipska, B., Jaskiw, G. E., Wong, D. T., Robertson, D. W., Weinberger, D. R., and Kleinman, J. E. 1993. Serotonin 5-HT3 receptors in schizophrenia: a postmortem study of the amygdala. Brain Res. 616(1-2):53-7.
26. Krystal, J. H., Karper, L. P., Bennett, A., D'Souza, D. C., Abi-Dargham, A., Morrissey, K., Abi-Saab, D., Bremner, J. D., Bowers, M. B. Jr., Suckow, R. F., Stetson, P., Heninger, G. R., and Charney, D. S. 1998. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berl) 135(3):213-29.
27. Umbricht, D., Schmid, L., Koller, R., Vollenweider, F. X., Hell, D., and Javitt, D. C. 2000. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen. Psychiatry 57(12):1139-47.
28. Oranje, B., van Berckel, B. N., Kemner, C., van Ree, J. M., Kahn, R. S., and Verbaten, M. N. 2000. The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 22(3):293-302.
29. Jessen, F., Fries, T., Kucharski, C., Nishimura, T., Hoenig, K., Maier, W., Falkai, P., and Heun, R. 2001. Amplitude reduction of the mismatch negativity in first-degree relatives of patients with schizophrenia. Neurosci. Lett. 309(3):185-8.
30. al-Amin, H. A. and Schwarzkopf, S. B. 1996. Effects of the PCP analog dizocilpine on sensory gating: potential relevance to clinical subtypes of schizophrenia. Biol. Psychiatry 40(8):744-54.
31. Bakshi, V. P. and Geyer, M. A. 1999. Ontogeny of isolation rearing-induced deficits in sensorimotor gating in rats. Physiol. Behav. 67(3):385-92.
32. de Bruin, N. M., Ellenbroek, B. A., Cools, A. R., Coenen, A. M., and van Luijtelaar, E. L. 1999. Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats. Psychopharmacology (Berl) 142(1):9-17.
33. Duncan, E. J., Madonick, S. H., Parwani, A., Anglist, B., Rajan, R., Chakravorty, S., Efferen, T. R., Szilagyi, S., Stephanides, M., Chappell, P. B., Gonzenbach, S., Ko, G. N., and Rotrosen, J. P. 2001. Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology 25(1):72-83.
34. Furuya, Y. and Ogura, H. 1997. Competitive NMDA and strychnine- insensitive glycine-site antagonists disrupt prepulse inhibition. Pharmacol. Biochem. Behav. 57(4):909-13.
35. Martinez, Z. A., Halim, N. D., Oostwegel, J. L., Geyer, M. A., and Swerdlow, N. R. 2000. Ontogeny of phencyclidine and apomorphine-induced startle gating deficits in rats. Pharmacol. Biochem. Behav. 65(3):449-57.
36. van Berckel, B. N., Oranje, B., van Ree, J. M., Verbaten, M. N., and Kahn, R. S. 1998. The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology (Berl) 137(3):271-81.
37. LaBossiere, E. and Glickstein, M. 1976. Histological processing for the neural science. Charles C. Thomas, Springfield, pp. 41-43.
38. Siegel, S. J., Connolly, P., Liang, Y., Lenox, R. H., Gur, R. E., Bilker, W. B., Kanes, S. J., and Turetsky, B. I. 2003. Effects of strain, novelty, and NMDA blockade on auditory-evoked potentials in mice. Neuropsychopharmacology 28(4):675-82.
39. Connolly, P. M., Maxwell, C. R., Kanes, S. J., Abel, T., Liang, Y., Tokarczyk, J., Bilker, W. B., Turetsky, B. I., Gur, R. E., and Siegel, S. J. 2003. Auditory evoked potentials, startle and pre-pulse inhibition in DBA/2J and DBA/2Hsd inbred mouse sub-strains. Brain Res. 992(1):85-95.
40. Umbricht, D. S., Latanov, A., Vissotksi, D., Nitsch, R., and Lipp, H. P. 2002. Development of a mouse model of deficits in prettentive auditory processing in schizophrenia. Biol. Psychiatry 51(8S):64S.
41. Maxwell, C. R., Liang, Y., Weightman, B. D., Kanes, S. J., Abel, T., Gur, R. E., Turetsky, B. I., Bilker, W. B., Lenox, R. H., and Siegel, S. J. 2004. Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential. Neuropsychopharmacology.
42. Cook, J. D., Ellinwood, E. H. Jr., and Wilson, W. P. 1968. Auditory habituation at primary cortex as a function of stimulus rate. Exp. Neurol. 21(2):167-75.
43. Stevens, K. E., Johnson, R. G., and Rose, G. M. 1997. Rats reared in social isolation show schizophrenia-like changes in auditory gating. Pharmacol. Biochem. Behav. 58(4):1031-6.
44. Stevens, K. E., Luthman, J., Lindqvist, E., Johnson, R. G., and Rose, G. M. 1996. Effects of neonatal dopamine depletion on sensory inhibition in the rat. Pharmacol. Biochem. Behav. 53(4): 817-23.
45. Stevens, K. E., Bullock, A. E., and Collins, A. C. 2001. Chronic corticosterone treatment alters sensory gating in C3H mice. Pharmacol. Biochem. Behav. 69(3-4):359-66.
46. Stevens, K. E., Kem, W. R., and Freedman, R. 1999. Selective alpha 7 nicotinic receptor stimulation normalizes chronic cocaine-induced loss of hippocampal sensory inhibition in C3H mice. Biol. Psychiatry 46(10):1443-50.
47. Stevens, K. E., Kem, W. R., Mahnir, V. M., and Freedman, R. 1998. Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology (Berl) 136(4):320-7.
48. Stevens, K. E., Meltzer, J., and Rose, G. M. 1995. Nicotinic cholinergic normalization of amphetamine-induced loss of auditory gating in freely moving rats. Psychopharmacology (Berl) 119(2):163-70.
49. Stevens, K. E. and Wear, K. D. 1997. Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models. Pharmacol. Biochem. Behav. 57(4):869-74.
50. de Bruin, N. M., Ellenbroek, B. A., van Schaijk, W. J., Cools, A. R., Coenen, A. M., and van Luijtelaar, E. E. 2001. Sensory gating of auditory evoked potentials in rats: effects of repetitive stimulation and the interstimulus interval. Biol. Psychol. 55(3):195-213.
51. Kreitschmann-Andermahr, I., Rosburg, T., Demme, U., Gaser, E., Nowak, H., and Sauer, H. 2001. Effect of ketamine on the neuromagnetic mismatch field in healthy humans. Brain Res. Cogn. Brain Res. 12(1):109-16.
52. Shelley, A. M., Silipo, G., and Javitt, D. C. 1999. Diminished responsiveness of ERPs in schizophrenic subjects to changes in auditory stimulation parameters: implications for theories of cortical dysfunction. Schizophr. Res. 37(1):65-79.
53. Ogura, C., Nageishi, Y., Matsubayashi, M., Omura, F., Kishimoto, A., and Shimokochi, M. 1991. Abnormalities in event-related potentials, N100, P200, P300 and slow wave in schizophrenia. Jpn. J. Psychiatry Neurol. 45(1):57-65.
54. Geyer, M. A. 1998. Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research. Pharmacopsychiatry 31 (Suppl 2):73-9.
55. Ford, J. M., Roth, W. T., Menon, V., and Pfefferbaum, A. 1999. Failures of automatic and strategic processing in schizophrenia: comparisons of event-related brain potential and startle blink modification. Schizophr. Res. 37(2):149-63.
56. Umbricht, D., Koller, R., Vollenweider, F. X., and Schmid, L. 2002. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol. Psychiatry 51(5):400-6.
57. Javitt, D. C., Jayachandra, M., Lindsley, R. W., Specht, C. M., and Schroeder, C. E. 2000. Schizophrenia-like deficits in auditory P1 and N1 refractoriness induced by the psychomimetic agent phencyclidine (PCP). Clin. Neurophysiol. 111(5):833-6.
58. Ehlers, C. L., Kaneko, W. M., Wall, T. L., and Chaplin, R. I. 1992. Effects of dizocilpine (MK-801) and ethanol on the EEG and event-related potentials (ERPS) in rats. Neuropharmacology 31(4):369-78.
59. Roth, W. T., Pfefferbaum, A., Kelly, A. F., Berger, P. A., and Kopell, B. S. 1981. Auditory event-related potentials in schizophrenia and depression. Psychiatry Res. 4(2):199-212.
60. Kroner, S., Schall, U., Ward, P. B., Sticht, G., Banger, M., Haffner, H. T., and Catts, S. V. 1999. Effects of prepulses and d-amphetamine on performance and event-related potential measures on an auditory discrimination task. Psychopharmacology (Berl) 145(2):123-32.
61. Weiner, I. 2003. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl). 169(3/4):257-297.
62. Ito, C. 2002. Analysis of overall gene expression induced by amphetamine and phencyclidine: novel targets for the treatment of drug psychosis and schizophrenia. Curr. Pharm. Des. 8(2):147-53.
63. Ralph, R. J., Varty, G. B., Kelly, M. A., Wang, Y. M., Caron, M. G., Rubinstein, M., Grandy, D. K., Low, M. J., and Geyer, M. A. 1999. The dopamine D2, but not D3 or D4, receptor-subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J. Neurosci. 19(11): 4627-33.
64. Jansen, K. L. and Darracot-Cankovic, R. 2001. The nonmedical use of ketamine, part two: a review of problem use and dependence. J. Psychoactive Drugs 33(2):151-8.
65. Hemby, S. E., Ginsberg, S. D., Brunk, B., Arnold, S. E., Trojanowski, J. Q., and Eberwine, J. H. 2002. Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex. Arch Gen. Psychiatry 59(7): 631-40.
66. Vysokanov, A., Flores-Hernandez, J., and Surmeier, D. J. 1998. mRNAs for clozapine-sensitive receptors co-localize in rat prefrontal cortex neurons. Neurosci. Lett. 258(3):179-82.
67. Simosky, J. K., Stevens, K. E., Kem, W. R., and Freedman, R. 2001. Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice. Biol. Psychiatry 50(7):493-500.
68. Simosky, J. K., Stevens, K. E., Adler, L. E., and Freedman, R. 2003. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology (Berl) 165(4):386-96.